INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
February 08, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
January 25, 2022 05:23 ET
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
December 21, 2021 09:39 ET
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Therapeutic Dog Food Market Size Worth $8,949.52 Million, Globally, by 2028 at 5.6% CAGR - Exclusive Report by The Insight Partners
December 16, 2021 05:41 ET
|
The Insight Partners
New York, Dec. 16, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Therapeutic Dog Food Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Dry Food,...
Center for Allergy & Asthma of Georgia Partners with Southern Ear, Nose, Throat and Allergy Physicians
November 19, 2021 09:00 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital, a leading investment bank to physician group practices, healthcare services and technology companies nationally, is pleased to...
Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
November 17, 2021 09:30 ET
|
Allovate, LLC
New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...
Tai Ji Men Qigong Academy in Los Angeles Celebrates Its 21st Anniversary with Love and Conscience
September 28, 2021 19:20 ET
|
Tai Ji Men Qigong Academy
LOS ANGELES, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Tai Ji Men Qigong Academy in Los Angeles celebrated its 21st birthday on September 26, 2021. Because the Delta variant of COVID-19 is rapidly...
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
September 21, 2021 05:53 ET
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...